14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $33.24 $45.00 Wednesday, 24th Apr 2024 CRBP stock ended at $35.54. This is 5.83% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 11.97% from a day low at $34.24 to a day high of $38.34.
90 days $7.49 $49.87
52 weeks $3.03 $49.87

Historical Corbus Pharmaceuticals Holdings prices

Date Open High Low Close Volume
Mar 19, 2024 $39.50 $43.86 $39.50 $42.76 122 495
Mar 18, 2024 $43.13 $43.13 $39.01 $41.62 236 403
Mar 15, 2024 $45.55 $46.74 $42.28 $43.68 489 557
Mar 14, 2024 $45.31 $48.02 $43.98 $45.13 295 860
Mar 13, 2024 $46.36 $49.87 $45.15 $47.08 476 371
Mar 12, 2024 $40.12 $45.33 $39.82 $44.58 315 320
Mar 11, 2024 $43.49 $43.49 $37.01 $38.28 408 192
Mar 08, 2024 $39.62 $46.19 $38.15 $44.93 770 229
Mar 07, 2024 $35.86 $42.60 $35.86 $40.32 887 095
Mar 06, 2024 $38.95 $38.99 $33.58 $33.58 191 618
Mar 05, 2024 $36.00 $38.06 $32.17 $34.60 438 620
Mar 04, 2024 $34.79 $37.80 $33.50 $36.32 369 844
Mar 01, 2024 $30.81 $35.00 $30.36 $35.00 334 842
Feb 29, 2024 $28.25 $31.51 $26.82 $30.90 647 397
Feb 28, 2024 $25.61 $28.49 $25.21 $28.00 140 402
Feb 27, 2024 $28.65 $28.65 $26.07 $26.07 243 655
Feb 26, 2024 $25.96 $29.00 $25.01 $28.52 179 320
Feb 23, 2024 $25.26 $26.25 $24.93 $25.75 208 002
Feb 22, 2024 $27.20 $27.69 $24.11 $25.45 192 562
Feb 21, 2024 $23.76 $28.56 $23.68 $27.15 815 762
Feb 20, 2024 $23.80 $23.95 $23.20 $23.30 117 953
Feb 16, 2024 $22.31 $24.14 $21.97 $23.10 259 300
Feb 15, 2024 $22.28 $23.20 $22.00 $22.48 82 756
Feb 14, 2024 $22.66 $24.35 $21.76 $22.50 129 659
Feb 13, 2024 $21.88 $23.22 $21.31 $22.00 107 522
Click to get the best stock tips daily for free!

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the act... CRBP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT